Clinical trial
Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated…
NCT00389987 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00389987 |
|---|---|
| Title | Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037) |
| Official title | A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Complicated Intra-Abdominal Infections |
| Intervention type | Drug |
| Interventions | MK0826, /Duration of Treatment : 8 Weeks, Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks |
| Enrollment | 300 |
| Start date | Sep 1, 2001 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Oct 19, 2006 |
| Last update posted | Feb 17, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: